Out of market

You are entering a site intended for residents outside U.S. and U.K. in the healthcare sector.

Cancel

Hospital efficiency starts in the operating room.

Reducing the length of hospital stay, associated with fewer complications when using TachoSil®

When surgical
complexity rises,
efficiency matters.

Europe’s ageing population is driving an increase in both the demand for surgery and complexity of procedures.1 As hospital reimbursement per case remains fixed, achieving better outcomes with existing resources has become essential.

TachoSil supports reliable hemostasis2-4 and tissue sealing,5-6 helping reduce variability linked to postoperative complications.

By minimizing complications, TachoSil may help reduce hospital stays by up to 11.8 days,2-3,7 supporting hospital efficiency and helping reduce surgical costs in an increasingly demanding healthcare environment.

List Item Icon Faster hemostasis.
List Item Icon Reducing complications.
List Item Icon Shorter hospital stays.

Reduction of complications reduces surgical costs.

Loss of efficiency due to complications.

Complications erode efficiency, extending hospital stays and consuming hospital capacity8. The occurrence of complications increase the cost by a factor of 2-4.9 The result is a deficit.

Reducing costs by reducing complications.

Avoiding complications reduces the length of hospital stay and lowers costs within the flat rate per case.2-3

TachoSil – reducing complications to protect hospital performance.

When standard techniques are insufficient, TachoSil supports reliable hemostasis2-4 and tissue sealing5-6. By helping surgeons control bleeding and leakage quickly, it reduces complication-related variability and supports shorter hospital stays2-3,7.

See how TachoSil® works SmPc

Shorter hospital stays from 0.5 to 11.8 days2-3. Proven with TachoSil.

Clinical evidence across multiple surgical indications shows significant reductions in hospital stay when TachoSil is used.

2.4

days shorter stay for urology procedures5

2.7

days shorter stay for cardio surgery10

3.0

days shorter stay for liver surgery4

1.3 – 1.6

days shorter stay for thoracic surgery11-12

Reduction in postoperative complications.

The rapid and safe reduction of clinical complications such as prolonged air leaks, urine leakage, lymphoceles, or even bleeding7,13,14 can enable earlier discharge of patients10,14-17 and minimize re-interventions.

1 2 3 4 5 6 7
1
Reduction of postoperative CSF fistulas and cerebrospinal fluid leaks
  • Supportive mechanical sealing of the dura mater to reduce leakage18
  • Significant reduction in length of hospital stay§,16
  • Shortening of monitoring time in intermediate care units§,16
  • Reduction in cost-intensive reinterventions due to supportive multilayer dura closure18
2
Reduction of pericardial effusions
  • Significant reduction in postoperative pericardial effusion volume and shortening of drainage duration#,10
  • Significantly lower risk of (pre-)tamponades requiring pericardiocentesis10
3
Reduction of persistent air leaks and postoperative blood loss
  • Significant reduction in air leak intensity13 and duration14,17 as well as reduction in leakage rate in complex reoperations6
  • Shortening of drainage duration and accelerated discharge of patients&,14,17
  • Significant reduction of procedural costs through efficient complication management17
4
Reduction of postoperative bleeding

Significant reduction in postoperative drainage volume compared to oxidized cellulose$,15

5
Reduction of urine leakage

Process optimization through catheter-free PCNL and early discharge of patients5

6
Reduction of lymphoceles

Reduction in drainage volume (e.g., Lymphatic adverse events (LAEs) after radical prostatectomy, laparoscopic partial kidney resection)19-20

7
Reduction of lymphoceles

Reduction in drainage volume (e.g., Lymphatic adverse events (LAEs) after radical prostatectomy, laparoscopic partial kidney resection)19-20

Efficiency in the operating room through faster hemostasis.

The adjunctive use of TachoSil supports faster hemostasis, helping to streamline surgical procedures and optimize operating room resources.

4,2
minutes can be saved in partial nephrectomy.
Median time to hemostasis was reduced from 9.3 minutes to 5.3 minutes (p < 0.0001).Ø,21
1
minute can be saved in hepatectomy.
Median time to hemostasis was reduced from 4 minutes to 3 minutes (p = 0.0007).‡,22

A trusted name worldwide.

Used in operating rooms around the world, TachoSil® stands for reliability, safety, and consistent surgical performance — wherever it’s needed.

Get in touch

References


1: European Commission: Green Paper on Ageing, 2021. Available at: https://commission.europa.eu/system/files/2021-06/green_paper_ageing_2021_en.pdf, last accessed on 12 January 2026 2: Colombo GL et al. Vasc Health Risk Manag. 2014; 10: 569-576
3: Colombo GL et al. Ther Clin Risk Manag. 2025; 21: 261-70
4: Briceno J et al. Arch Surg 2010; 145: 482-4
5: Cormio L et al. J Urol. 2012; 188(1): 145-50
6: Filosso PL et al. Interact Cardiovasc Thorac Surg. 2013; 16(5): 661-6
7: Summary of Product Characteristics TachoSil® sealant matrix, current status
8: Ladant FX et al. BMJ Surg Interv Health Technol. 2025; 7(1): e000323
9: Watson SL et al. Br J Anaesth. 2025; 135(6): 1753-1760
10: Onorati F et al. J Card Surg. 2008; 23(6): 531-6
11: Rena O et al. Interact Cardiovasc Thorac Surg 2009; 9: 973-977
12: Allama AM et al. Asian Cardiovascular and Thoracic Annals. 2019; 27(5): 369-373
13: Marta GM et al. Eur J Cardiothorac Surg. 2010; 38(6): 683-9
14: Anegg U et al. Eur J Cardiothorac Surg. 2007; 31(2): 198-202
15: Kakaei F et al. HPB Surgery. 2013; 2013: 587608
16: Hutter M et al. J Neurosurg. 2014; 121(5): 735-744
17: Droghetti A et al. Ann Thorac Surg. 2008; 86(4): 1126-31
18: Tamašauskas A et al. J Clin Neurosci. 2008; 15(11): 1273-7
19: Simonato A et al. Eur Urol. 2009; 55(1): 12-19
20: Tonyali S et al. Urol Int. 2016; 96(3): 328-33
21: Siemer S et al. Eur Urol 2007; 52(4): 1156-63;
22: Frilling A et al. Langenbecks Arch Surg 2005; 390: 114-20;
#: Onorati F et al. 2008: Prospective cohort study (n = 29);
$: Kakaei F et al. 2013: RCT with limited sample size (n = 45), comparing TachoSil®, oxidized cellulose, and cyanoacrylate adhesive (n = 15 per group);
&: Droghetti A et al. 2008: Proven in pilot study;
Ø: Siemer S et al. 2007: Marginal prolapse study, TachoSil® vs. standard technique (suture), (n = 185);
‡: Frilling A et al. 2005: RCT, TachoSil® (n = 59) vs. Argonbeamer (n = 62).
TACHOSIL® SmPC
List Item Icon
Links to regional SMPC:

  • EMA SmPC: https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil
  • UK SmPC: https://products.mhra.gov.uk/search/?search=tachosil&page=1
  • USA SmPC: https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/tachosil
  • Switzerland SmPC:
    Facebook twitter LinkedIn Instagram Youtube
    Solutions Arrow
    Biomedical Textiles Biosurgery Ophthalmology Wound Closure
    Company Arrow
    About Careers Leadership News & Events Resources
    Customer Service Arrow
    Email service@corza.com Phone +1-877-991-1110 Fax +1-610-404-4010
    © 2026 Corza Medical. All Rights Reserved.
    Privacy Policy Ethics & Compliance Terms & Conditions